抗GBM病中循环IgA抗GBM自身抗体的患病率与特征
该研究用ELISA检测107例抗GBM病患者和115例对照的循环IgA抗α3(IV)NC1抗体,发现18.7%(20/107)患者阳性且健康对照和其他肾小球疾病患者未检出。IgA阳性患者循环IgG抗α3(IV)NC1抗体滴度显著高于阴性患者,但两组肾脏结局和死亡率无显著差异。
要点
- 抗GBM病患者中循环IgA抗α3(IV)NC1抗体阳性率为18.7%(20/107),健康对照和其他肾小球疾病患者未检出。
- IgA阳性患者循环IgG抗α3(IV)NC1抗体滴度显著高于阴性患者(200 [183.3, 200] vs. 161 [85.5, 200] U/ml,P = 0.005)。
- 两组肾脏免疫荧光IgA沉积比例无统计学差异(30.0% vs. 40.4%,P = 0.725),肾脏结局和死亡率无显著差异。
核心结论
- 循环IgA抗α3(IV)NC1抗体在抗GBM病患者中占18.7%(20/107),且对抗GBM病具有特异性。
- IgA阳性患者血清IgG抗α3(IV)NC1抗体水平高于IgA阴性患者,但两组肾脏结局和死亡率无显著差异。
研究设计与样本
- 回顾性分析107例抗GBM病患者和115例对照,用ELISA检测循环IgA抗α3(IV)NC1抗体,并分析临床、病理和随访数据。
主要发现
- 循环IgA抗α3(IV)NC1抗体在抗GBM病患者中阳性率为18.7%(20/107),健康对照和其他肾小球疾病患者未检出。
- IgA阳性与是否合并IgA肾病或其他肾小球肾炎无关。
- 肾脏免疫荧光IgA沉积在IgA阳性组与阴性组间无统计学差异(30.0% vs. 40.4%,P = 0.725)。
- IgA阳性组循环IgG抗α3(IV)NC1抗体滴度显著高于阴性组(200 [183.3, 200] vs. 161 [85.5, 200] U/ml,P = 0.005)。
- 两组肾脏结局和死亡率无显著差异。
关键数值与推荐
- 循环IgA抗α3(IV)NC1抗体阳性率18.7%(20/107)。
- IgA阳性组vs阴性组循环IgG抗α3(IV)NC1抗体滴度:200 [183.3, 200] vs. 161 [85.5, 200] U/ml,P = 0.005。
- IgA阳性组vs阴性组肾脏免疫荧光IgA沉积比例:30.0% vs. 40.4%,P = 0.725。
临床怎么用
- 在抗GBM病中可检测循环IgA抗α3(IV)NC1抗体,其阳性提示IgG抗α3(IV)NC1抗体滴度可能更高。
- 循环IgA抗α3(IV)NC1抗体阳性与否未显示与肾脏结局或死亡率相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In some cases, immunoglobulin (IgA)-mediated antiglomerular basement membrane (anti-GBM) disease has been reported. Whether circulating IgA anti-GBM antibodies affect the clinico-pathologic characteristics and outcome of typical anti-GBM disease deserves further study. METHODS: Circulating IgA anti-α3(IV)NC1 antibodies were examined by enzyme-linked immunosorbent assay (ELISA) using recombinant human α3(IV)NC1 as solid phase antigens in 107 patients with anti-GBM disease and 115 controls. Clinical, pathological, and follow-up data of patients were retrospectively analyzed. RESULTS: Circulating IgA anti-α3(IV)NC1 antibodies were found in 18.7% (20/107) of patients with anti-GBM disease but were not detected in healthy controls or in patients with other glomerular diseases. The positivity of circulating IgA anti-α3(IV)NC1 antibodies was not associated with whether the patient was with combined IgA nephropathy or other glomerulonephritis. Kidney immunofluorescence showed no statistical difference in IgA deposition between patients with circulating IgA anti-α3(IV)NC1 antibodies and patients without (30.0% vs. 40.4%, P = 0.725). The titers of circulating immunoglobulin G (IgG) anti-α3(IV)NC1 antibodies in patients with circulating IgA anti-α3(IV)NC1 antibodies were significantly higher than those without (200 [183.3, 200] vs. 161 [85.5, 200] U/ml, P = 0.005). There were no significant differences in kidney outcome and mortality between the 2 groups. CONCLUSION: Circulating IgA anti-α3(IV)NC1 antibodies occurred in 18.7% (20/107) of patients with anti-GBM in our center and were specific to anti-GBM disease. Patients with circulating IgA anti-α3(IV)NC1 antibodies showed a higher levels of serum IgG anti-α3(IV)NC1 antibodies than those without.
引用
- Yang XF, Kuang H, Shen CR, et al. The Prevalence and Characteristics of Circulating IgA Anti-Glomerular Basement Membrane Autoantibodies in Anti-Glomerular Basement Membrane Disease. Kidney Int Rep. 2023. PMID: 38025241. doi:10.1016/j.ekir.2023.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。